Molecular interaction studies of HIV-1 matrix protein p17 and heparin: Identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists

Journal of Biological Chemistry

Volumn 288, Issue 2, 2013, Pages 1150-1161

  Bugatti, Antonella ^a   Giagulli, Cinzia ^a   Urbinati, Chiara ^a   Caccuris, Francesca ^a   Chiodelli, Paola ^a   Oreste, Pasqua ^b   Fiorentini, Simona ^a   Orro, Alessandro ^c   Milanesi, Luciano ^c   D'Ursi, Pasqualina ^c   Caruso, Arnaldo ^a   Rusnati, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Glycores 2000A 20155 ^*  (Italy)

^c Institute of Biomedical Technologies   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING DOMAIN; CELLULAR RECEPTORS; COMPUTATIONAL MODELING; DESULFATED HEPARIN; DESULFATION; GLYCOSAMINOGLYCANS; HEPARAN SULFATES; HEPARIN BINDING; HUMAN MONOCYTES; MATRIX PROTEINS; MOLECULAR LEVELS; MULTITARGET; N-TERMINALS; PROTEOGLYCANS; SITE DIRECTED MUTAGENESIS; SULFATE GROUPS; VIRAL PROTEINS;

AMINO ACIDS; DISEASES; ENZYME ACTIVITY; ESCHERICHIA COLI; PROTEINS;

POLYSACCHARIDES;

ALANINE; AMINO ACID; ARGININE; CHEMOKINE RECEPTOR CXCR1; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HEPARIN DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; MATRIX PROTEIN; PROTEIN P17;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; CHEMOTAXIS; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SULFATION; ESCHERICHIA COLI; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMOBILIZATION; MOLECULAR INTERACTION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SITE DIRECTED MUTAGENESIS; SURFACE PLASMON RESONANCE;

AMINO ACID SEQUENCE; CHEMOTAXIS, LEUKOCYTE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HEPARIN; HIV ANTIGENS; HUMANS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PROTEIN BINDING; SURFACE PLASMON RESONANCE;

ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84872342951     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.400077     Document Type: Article

References (65)

1. Fiorentini, S., Riboldi, E., Facchetti, F., Avolio, M., Fabbri, M., Tosti, G., Becker, P. D., Guzman, C. A., Sozzani, S., and Caruso, A. (2008) HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype. Proc. Natl. Acad. Sci. U.S.A. 105, 3867-3872 (Pubitemid 351723491)
2. Bryant, M., and Ratner, L. (1990) Myristoylation-dependent replication and assembly of human immunodeficiency virus 1. Proc. Natl. Acad. Sci. U.S.A. 87, 523-527
3. Cannon, P. M., Matthews, S., Clark, N., Byles, E. D., Iourin, O., Hockley, D. J., Kingsman, S. M., and Kingsman, A. J. (1997) Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17. J. Virol. 71, 3474-3483 (Pubitemid 27172358)
4. Budka, H. (1990) Human immunodeficiency virus (HIV) envelope and core proteins in CNS tissues of patients with the acquired immune deficiency syndrome (AIDS). Acta Neuropathol. 79, 611-619
5. Popovic, M., Tenner-Racz, K., Pelser, C., Stellbrink, H. J., van Lunzen, J., Lewis, G., Kalyanaraman, V. S., Gallo, R. C., and Racz, P. (2005) Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc. Natl. Acad. Sci. U.S.A. 102, 14807-14812 (Pubitemid 41457137)
6. Fiorentini, S., Giagulli, C., Caccuri, F., Magiera, A. K., and Caruso, A. (2010) HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS. Pharmacol. Ther. 128, 433-444
7. De Francesco, M. A., Baronio, M., Fiorentini, S., Signorini, C., Bonfanti, C., Poiesi, C., Popovic, M., Grassi, M., Garrafa, E., Bozzo, L., Lewis, G. K., Licenziati, S., Gallo, R. C., and Caruso, A. (2002) HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. Proc. Natl. Acad. Sci. U.S.A. 99, 9972-9977 (Pubitemid 34831157)
8. De Francesco, M. A., Poiesi, C., Ricotta, D., and Manca, N. (2006) HIV p17 reverses the anti-inflammatory activity of IL-4 on IL-15 stimulated monocytes and modulates their ability to secrete MIP-1 α. Virus Res. 118, 170-177
9. De Francesco, M. A., Caruso, A., Fallacara, F., Canaris, A. D., Dima, F., Poiesi, C., Licenziati, S., Corulli, M., Martinelli, F., Fiorentini, S., and Turano, A. (1998) HIV p17 enhances lymphocyte proliferation and HIV-1 replication after binding to a human serum factor. Aids 12, 245-252 (Pubitemid 28045452)
10. Vitale, M., Caruso, A., De Francesco, M. A., Rodella, L., Bozzo, L., Garrafa, E., Grassi, M., Gobbi, G., Cacchioli, A., and Fiorentini, S. (2003) HIV-1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases their ability to secrete proinflammatory cytokines. Br. J. Haematol. 120, 337-343 (Pubitemid 36194187)
11. Giagulli, C., Magiera, A. K., Bugatti, A., Caccuri, F., Marsico, S., Rusnati, M., Vermi, W., Fiorentini, S., and Caruso, A. (2012) HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8-like chemokine activity on monocytes through Rho/ROCK activation. Blood 119, 2274-2283
12. Caccuri, F., Giagulli, C., Bugatti, A., Benetti, A., Alessandri, G., Ribatti, D., Marsico, S., Apostoli, P., Slevin, M. A., Rusnati, M., Guzman, C. A., Fiorentini, S., and Caruso, A. (2012) HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc. Natl. Acad. Sci. U.S.A. 109, 14580-14585
13. Poiesi, C., De Francesco, M. A., Baronio, M., and Manca, N. (2008) HIV-1 p17 binds heparan sulfate proteoglycans to activated CD4(+) T cells. Virus Res. 132, 25-32 (Pubitemid 351232079)
14. De Francesco, M. A., Baronio, M., and Poiesi, C. (2011) HIV-1 p17 matrix protein interacts with heparan sulfate side chain of CD44v3, syndecan-2, and syndecan-4 proteoglycans expressed on human activated CD4+ T cells affecting tumor necrosis factor α and interleukin 2 production. J. Biol. Chem. 286, 19541-19548
15. Lindahl, U., Lidholt, K., Spillmann, D., and Kjellén, L. (1994) More to "heparin" than anticoagulation. Thromb. Res. 75, 1-32
16. Turnbull, J., Powell, A., and Guimond, S. (2001) Heparan sulfate: decoding a dynamic multifunctional cell regulator. Trends Cell Biol. 11, 75-82 (Pubitemid 32144754)
17. Spillmann, D. (2001) Heparan sulfate: anchor for viral intruders? Biochimie 83, 811-817
18. Rusnati, M., Vicenzi, E., Donalisio, M., Oreste, P., Landolfo, S., and Lembo, D. (2009) Sulfated K5 Escherichia coli polysaccharide derivatives: A novel class of candidate antiviral microbicides. Pharmacol. Ther. 123, 310-322
19. Coltrini, D., Rusnati, M., Zoppetti, G., Oreste, P., Grazioli, G., Naggi, A., and Presta, M. (1994) Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor. Biochem. J. 303, 583-590 (Pubitemid 24317343)
20. Bugatti, A., Urbinati, C., Ravelli, C., De Clercq, E., Liekens, S., and Rusnati, M. (2007) Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins. Antimicrob. Agents Chemother. 51, 2337-2345 (Pubitemid 47047308)
21. Rusnati, M., Urbinati, C., Caputo, A., Possati, L., Lortat-Jacob, H., Giacca, M., Ribatti, D., and Presta, M. (2001) Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. J. Biol. Chem. 276, 22420-22425
22. Goldstein, G. (1996) HIV-1 Tat protein as a potential AIDS vaccine. Nat. Med. 2, 960-964
23. Ai, J., Xin, X., Zheng, M., Wang, S., Peng, S., Li, J., Wang, L., Jiang, H., and Geng, M. (2008) A triad of lys12, lys41, arg78 spatial domain, a novel identified heparin binding site on tat protein, facilitates tat-driven cell adhesion. PLoS One 3, e2662
24. Rusnati, M., Coltrini, D., Oreste, P., Zoppetti, G., Albini, A., Noonan, D., d'Adda di Fagagna, F., Giacca, M., and Presta, M. (1997) Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. J. Biol. Chem. 272, 11313-11320 (Pubitemid 27184133)
25. Rusnati, M., Tulipano, G., Spillmann, D., Tanghetti, E., Oreste, P., Zoppetti, G., Giacca, M., and Presta, M. (1999) Multiple interactions of HIV-I Tat protein with size-defined heparin oligosaccharides. J. Biol. Chem. 274, 28198-28205
26. Moulard, M., Lortat-Jacob, H., Mondor, I., Roca, G., Wyatt, R., Sodroski, J., Zhao, L., Olson, W., Kwong, P. D., and Sattentau, Q. J. (2000) Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74, 1948-1960 (Pubitemid 30434054)
27. Crublet, E., Andrieu, J. P., Vivès, R. R., and Lortat-Jacob, H. (2008) The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site. J. Biol. Chem. 283, 15193-15200
28. Ping, L. H., Nelson, J. A., Hoffman, I. F., Schock, J., Lamers, S. L., Goodman, M., Vernazza, P., Kazembe, P., Maida, M., Zimba, D., Goodenow, M. M., Eron, J. J., Jr., Fiscus, S. A., Cohen, M. S., and Swanstrom, R. (1999) Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J. Virol. 73, 6271-6281 (Pubitemid 29327803)
29. Lopalco, L., Ciccomascolo, F., Lanza, P., Zoppetti, G., Caramazza, I., Leoni, F., Beretta, A., and Siccardi, A. G. (1994) Anti-HIV type 1 properties of chemically modified heparins with diminished anticoagulant activity. AIDS Res. Hum. Retroviruses 10, 787-793 (Pubitemid 24243570)
30. Rider, C. C., Coombe, D. R., Harrop, H. A., Hounsell, E. F., Bauer, C., Feeney, J., Mulloy, B., Mahmood, N., Hay, A., and Parish, C. R. (1994) Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. Biochemistry 33, 6974-6980 (Pubitemid 24190823)
31. Vicenzi, E., Gatti, A., Ghezzi, S., Oreste, P., Zoppetti, G., and Poli, G. (2003) Broad spectrum inhibition of HIV-1 infection by sulfated K5 Escherichia coli polysaccharide derivatives. Aids 17, 177-181 (Pubitemid 36183042)
32. Vivès, R. R., Imberty, A., Sattentau, Q. J., and Lortat-Jacob, H. (2005) Heparan sulfate targets the HIV-1 envelope glycoprotein gp120 coreceptor binding site. J. Biol. Chem. 280, 21353-21357
33. Matthews, S., Barlow, P., Clark, N., Kingsman, S., Kingsman, A., and Campbell, I. (1995) Refined solution structure of p17, the HIV matrix protein. Biochem. Soc. Trans. 23, 725-729
34. Hill, C. P., Worthylake, D., Bancroft, D. P., Christensen, A. M., and Sundquist, W. I. (1996) Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc. Natl. Acad. Sci. U.S.A. 93, 3099-3104 (Pubitemid 26114370)
35. Massiah, M. A., Worthylake, D., Christensen, A. M., Sundquist, W. I., Hill, C. P., and Summers, M. F. (1996) Comparison of the NMR and X-ray structures of the HIV-1 matrix protein: evidence for conformational changes during viral assembly. Protein Sci. 5, 2391-2398 (Pubitemid 26424852)
36. Morris, G. M., Goodsell, D. S., Huey, R., and Olson, A. J. (1996) Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J. Comput. Aided Mol. Des. 10, 293-304 (Pubitemid 126712824)
37. Huey, R., Morris, G. M., Olson, A. J., and Goodsell, D. S. (2007) A semiempirical free energy force field with charge-based desolvation. J. Comput. Chem. 28, 1145-1152 (Pubitemid 46506716)
38. Hetényi, C., and van der Spoel, D. (2002) Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci. 11, 1729-1737
39. Hetényi, C., and van der Spoel, D. (2006) Blind docking of drug-sized compounds to proteins with up to a thousand residues. FEBS Lett. 580, 1447-1450
40. Sali, A., and Blundell, T. L. (1993) Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 234, 779-815 (Pubitemid 24007801)
41. Van Der Spoel, D., Lindahl, E., Hess, B., Groenhof, G., Mark, A. E., and Berendsen, H. J. (2005) GROMACS: fast, flexible, and free. J. Comput. Chem. 26, 1701-1718 (Pubitemid 43076182)
42. Laskowski, R. A., Rullmannn, J. A., MacArthur, M. W., Kaptein, R., and Thornton, J. M. (1996) AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J. Biomol. NMR 8, 477-486 (Pubitemid 126706801)
43. Giagulli, C., Marsico, S., Magiera, A. K., Bruno, R., Caccuri, F., Barone, I., Fiorentini, S., Andò, S., and Caruso, A. (2011) Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS One 6, e17831
44. Isacchi, A., Statuto, M., Chiesa, R., Bergonzoni, L., Rusnati, M., Sarmientos, P., Ragnotti, G., and Presta, M. (1991) A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity. Proc. Natl. Acad. Sci. U.S.A. 88, 2628-2632 (Pubitemid 21916471)
45. Inoue, Y., and Nagasawa, K. (1976) Selective N-desulfation of heparin with dimethyl sulfoxide containing water or methanol. Carbohydr. Res. 46, 87-95
46. Casu, B., Grazioli, G., Razi, N., Guerrini, M., Naggi, A., Torri, G., Oreste, P., Tursi, F., Zoppetti, G., and Lindahl, U. (1994) Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr. Res. 263, 271-284 (Pubitemid 24320402)
47. Leali, D., Belleri, M., Urbinati, C., Coltrini, D., Oreste, P., Zoppetti, G., Ribatti, D., Rusnati, M., and Presta, M. (2001) Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J. Biol. Chem. 276, 37900-37908
48. Khalifa, M. B., Choulier, L., Lortat-Jacob, H., Altschuh, D., and Vernet, T. (2001) BIACORE data processing: an evaluation of the global fitting procedure. Anal. Biochem. 293, 194-203 (Pubitemid 32547904)
49. Fontana, L., Giagulli, C., Minuz, P., Lechi, A., and Laudanna, C. (2001) 8-Iso-PGF2 α induces β 2-integrin-mediated rapid adhesion of human polymorphonuclear neutrophils: a link between oxidative stress and ischemia/reperfusion injury. Arterioscler. Thromb. Vasc. Biol. 21, 55-60 (Pubitemid 32061927)
50. Coltrini, D., Rusnati, M., Zoppetti, G., Oreste, P., Isacchi, A., Caccia, P., Bergonzoni, L., and Presta, M. (1993) Biochemical bases of the interaction of human basic fibroblast growth factor with glycosaminoglycans. New insights from trypsin digestion studies. Eur. J. Biochem. 214, 51-58 (Pubitemid 23168517)
51. Rusnati, M., Tulipano, G., Urbinati, C., Tanghetti, E., Giuliani, R., Giacca, M., Ciomei, M., Corallini, A., and Presta, M. (1998) The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. J. Biol. Chem. 273, 16027-16037 (Pubitemid 28311370)
52. Rusnati, M., and Urbinati, C. (2009) Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis. Curr. Pharm. Des. 15, 2946-2957
53. Fernando, H., Nagle, G. T., and Rajarathnam, K. (2007) Thermodynamic characterization of interleukin-8 monomer binding to CXCR1 receptor N-terminal domain. FEBS J. 274, 241-251 (Pubitemid 44952912)
54. Fiorentini, S., Marini, E., Bozzo, L., Trainini, L., Saadoune, L., Avolio, M., Pontillo, A., Bonfanti, C., Sarmientos, P., and Caruso, A. (2004) Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH. Biopolymers 76, 334-343 (Pubitemid 39468256)
55. Urbinati, C., Bugatti, A., Oreste, P., Zoppetti, G., Waltenberger, J., Mitola, S., Ribatti, D., Presta, M., and Rusnati, M. (2004) Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. FEBS Lett. 568, 171-177 (Pubitemid 38757977)
56. Fiorentini, S., Marini, E., Caracciolo, S., and Caruso, A. (2006) Functions of the HIV-1 matrix protein p17. New Microbiol. 29, 1-10
57. Herbein, G., Gras, G., Khan, K. A., and Abbas, W. (2010) Macrophage signaling in HIV-1 infection. Retrovirology 7, 34
58. Corasaniti, M. T., Maccarrone, M., Nistico, R., Malorni, W., Rotiroti, D., and Bagetta, G. (2001) Exploitation of the HIV-1 coat glycoprotein, gp120, in neurodegenerative studies in vivo. J. Neurochem. 79, 1-8 (Pubitemid 32946636)
59. Chauhan, A., Turchan, J., Pocernich, C., Bruce-Keller, A., Roth, S., Butterfield, D. A., Major, E. O., and Nath, A. (2003) Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J. Biol. Chem. 278, 13512-13519 (Pubitemid 36800126)
60. Singh, I. N., Goody, R. J., Dean, C., Ahmad, N. M., Lutz, S. E., Knapp, P. E., Nath, A., and Hauser, K. F. (2004) Apoptotic death of striatal neurons induced by human immunodeficiency virus-1 Tat and gp120: Differential involvement of caspase-3 and endonuclease G. J. Neurovirol. 10, 141-151 (Pubitemid 38868152)
61. Rusnati, M., and Presta, M. (2002) HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. angiogenesis 5, 141-151
62. Lembo, D., Donalisio, M., Rusnati, M., Bugatti, A., Cornaglia, M., Cappello, P., Giovarelli, M., Oreste, P., and Landolfo, S. (2008) Sulfated K5 Escherichia coli polysaccharide derivatives as wide-range inhibitors of genital types of human papillomavirus. Antimicrob. Agents Chemother. 52, 1374-1381 (Pubitemid 351522001)
63. Hearps, A. C., and Jans, D. A. (2007) Regulating the functions of the HIV-1 matrix protein. AIDS Res. Hum. Retroviruses 23, 341-346 (Pubitemid 46608553)
64. Hoogewerf, A. J., Kuschert, G. S., Proudfoot, A. E., Borlat, F., Clark-Lewis, I., Power, C. A., and Wells, T. N. (1997) Glycosaminoglycans mediate cell surface oligomerization of chemokines. Biochemistry 36, 13570-13578 (Pubitemid 27481603)
65. Rusnati, M., and Presta, M. (1996) Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. Int. J. Clin. Lab. Res. 26, 15-23